IAP20 Reside TITTO 13 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In	re	api	plic	ation	of
	_				~

:

Takayuki DOI et al.

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2005 1863A

Filed December 13, 2005

PREVENTIVE/REMEDY FOR URINARY DISTURBANCE

[Corresponding to PCT/JP2004/009486 Filed June 29, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

la.

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

[X]	each U.S. Patent and U.S. Patent application publication;
[]	each reference previously cited in the international application PCT/; and/or
[]	each reference previously cited in prior parent application Serial No.
[X] Thi	s Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a

 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

JAP20 Radid	7770	13	DEC	2005
W 30 1	7.39	- C		LUUJ

- For each non-English language reference listed on the attached form PTO-1449, reference 4. is made to: a. [] a full or partial English language translation submitted herewith, b. [] a foreign patent office search report (in the English language) submitted herewith, the concise explanation contained in the specification of the present application c. [] at page, d. [] the concise explanation set forth in the attached English language abstract, e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [X] A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Takayuki DOI et al.

3v

Warren M. Cheek, Jr.

Registration No. 33,367

Attorney for Applicants

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 December 13,2005

Sheet 1 of 1			INFORMA	TION DISCLO	SURE STATEMENT			A 40 .	
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE				ATTY DOCI 2005_18	63A		14544	560754	
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Takayuki DOI et al. 13 DEC 2005					
		ral sheets if necessary) to PTO: December 13, 2	005	FILING DAT	re er 13, 2005		GROUP		
			U.	S. PATENT DO	OCUMENTS			<u> </u>	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	· CLASS		SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2002/0177593	11/2002	Ishil	nara et al.				Corresponds to AE
	АВ	5,527,800	6/1996	Go	oto et al.				
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	C	OUNTRY	CLASS		SUBCLASS	TRANSLATION YES NO
	AC	1 466 625	10/2004		EP				
.,	AD	2001/335576	12/2001		JP				Corresponds to AE Abstract
	AE	2000-169373	6/2000		JP				Abstract
	AF	03/057254	7/2003		wo				Abstract
	AG	7-206854	8/1995		JP				
	АН	0 607 864	9/2003		EP				Corresponds to AG
		OTHER	DOCUMENT(S) (/	ncluding Autho	or, Title, Date, Pertin	ent Page	s, Etc.)		
Al T. Nakahara et al., "The role of cholinesterases in rat urinary bladder contractility", Urol. Res., Vol. 31, pp. 223-226, 2003.									
	AJ	H. Nagabukuro et al., "Effects of TAK-802, A Novel Acetylcholinesterase Inhibitor, on Distension-Induced Rhythmic Bladder Contractions in Rats and Guinea Pigs", European Journal of Pharmacology, Vol. 285, pp. 299-305, 2004.							
	AK	H. Nagabukuro et al., "Effects of TAK-802, A Novel Acetylcholinesterase Inhibitor, on Isovolumetric Bladder Contractions in Rats and Guinea Pigs", The 10 th Nihonhainyoukinougakkai Program Abstract, July 2003, page 162 with English translation.							
	AL	T. Doi et al., "Effects of Tak-802, An Acetylcholinesterase Inhibitor, on Bladder Functions", Nihonhinyoukikagakkaishi, Vol. 95, No. 2, March 2004, page 41(161) with English translation.							
	АМ	N. Taniguchi et al., "Effects of TAK-802 in Pressure-Flow Study with Brain-Removed Cats", Nihonhinyoukikagakkaishi, Vol. 95, No. 2, March 2004, page 292(412) with English translation.							
	AN	H. Nagabukuro et al., "Effects of TAK-802, an Acetylcholinesterase Inhibitor, in a Sample of Isolated Bladder Muscle of Guinea Pigs", Nihonhinyoukikagakkaishi, Vol. 95, No. 2, March 2004, page 440(560) with English translation.							
	AO	H. Nagabukuro et al., "Effects of TAK-802, A Novel Acetylcholinesterase Inhibitor, on Urodynamics in Guinea Pigs, The 10 th Nihonhainyoukinougakkai Program Abstract, July 2003, page 163 with English translation.							
EXAMINER			DATE CONSIDERED						